Cardiol Therapeutics Files 6-K for February 2025
Ticker: CRDL · Form: 6-K · Filed: Feb 4, 2025 · CIK: 1702123
Sentiment: neutral
Topics: filing, regulatory-update, news-release
TL;DR
Cardiol Therapeutics filed a 6-K for Feb 2025, including a news release. Check for updates.
AI Summary
Cardiol Therapeutics Inc. filed a Form 6-K on February 4, 2025, reporting for the month of February 2025. The filing indicates that the company is a foreign private issuer and will file its annual reports under Form 20-F. The report includes Exhibit 99.1, which is a news release.
Why It Matters
This filing provides an update on Cardiol Therapeutics' reporting status and includes a news release, which may contain important operational or strategic information for investors.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not appear to contain significant new financial or operational disclosures beyond a news release.
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Filer of the 6-K report
- 001-40712 (dollar_amount) — SEC File Number
- 20250204 (date) — Filing date and period of report
- February 2025 (date) — Reporting period
- Form 20-F (company) — Annual report form
- Exhibit 99.1 (company) — Included exhibit
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report for the month of February 2025 and to submit Exhibit 99.1, which is a news release from Cardiol Therapeutics Inc.
What is Cardiol Therapeutics Inc.'s SEC File Number?
Cardiol Therapeutics Inc.'s SEC File Number is 001-40712.
What type of annual report does Cardiol Therapeutics Inc. file?
Cardiol Therapeutics Inc. files its annual reports under cover of Form 20-F.
On what date was this Form 6-K filed?
This Form 6-K was filed on February 4, 2025.
What is the business address of Cardiol Therapeutics Inc. as listed in the filing?
The business address of Cardiol Therapeutics Inc. is 602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5.
Filing Stats: 220 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2025-02-04 08:40:31
Filing Documents
- form6k.htm (6-K) — 6KB
- exhibit99-1.htm (EX-99.1) — 7KB
- exhibit99-1xu001.jpg (GRAPHIC) — 8KB
- 0001062993-25-001560.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: February 4, 2025 By: /s/ Chris Waddick Chris Waddick Title: Chief Financial Officer